Showing 1765 results
-
Story /John Tsai, Head of Global Drug Development and Chief Medical Officer, describes how he balances innovation and patient needs.
-
Press release /Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug…
-
Press release /Decision follows FDA request for additional information to complement submission for biosimilar rituximab Sandoz stands behind safety, efficacy and quality of our biosimilar rituximab, which is…
-
Press release /COVID-19 pandemic triggered a massive surge in virtual health and care delivery across the world, with many countries embracing hybrid virtual and in-person services Report from the Broadband…
-
Press release /Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly…
-
Event /Novartis is attending the World Economic Forum (WEF) Annual Meeting from January 20-24, 2025, in Davos, Switzerland. The meeting brings together nearly 3,000 leaders from over 130 countries, and 350…
-
Story /NIBR investigator develops technology that uses tumor DNA in the blood for diagnostics
-
Press release /Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65…
-
Press release /Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other…
-
Event /As part of our Eurovision celebration in Basel, Feel the Beat invites people with and without hearing impairments to come together on one dance floor and experience…